{"title":"Iron Oxide Nanoparticles Induce Macrophage Secretion of ATP and HMGB1 to Enhance Irradiation-Led Immunogenic Cell Death.","authors":"Shuyue Zhan, Zhengwei Cao, Jianwen Li, Fanghui Chen, Xinning Lai, Wei Yang, Yong Teng, Zibo Li, Weizhong Zhang, Jin Xie","doi":"10.1021/acs.bioconjchem.4c00488","DOIUrl":null,"url":null,"abstract":"<p><p>ATP (adenosine triphosphate) and HMGB1 (high mobility group box 1 protein) are key players in treatments that induce immunogenic cell death (ICD). However, conventional therapies, including radiotherapy, are often insufficient to induce ICD. In this study, we explore a strategy using nanoparticle-loaded macrophages as a source of ATP and HMGB1 to complement radiation-induced intrinsic and adaptive immune responses. To this end, we tested three inorganic particles, namely, iron oxide nanoparticles (ION), aluminum oxide nanoparticles (AON), and zinc oxide nanoparticles (ZON), <i>in vitro</i> with bone marrow-derived dendritic cells (BMDCs) and then <i>in vivo</i> in syngeneic tumor models. Our results showed that ION was the most effective of the three nanoparticles in promoting the secretion of ATP and HMGB1 from macrophages without negatively affecting macrophage survival. Secretions from ION-loaded macrophages can activate BMDCs. Intratumoral injection of ION-loaded macrophages significantly enhanced tumor infiltration and activation of dendritic cells and cytotoxic T cells. Moreover, exogenous ION macrophages can enhance the efficacy of radiotherapy. In addition, direct injection of ION can also enhance the efficacy of radiotherapy, which is attributed to ION uptake by and stimulation of endogenous macrophages. Instead of directly targeting cancer cells, our strategy targets macrophages and uses them as a secretory source of ATP and HMGB1 to enhance radiation-induced ICD. Our research introduces a new nanoparticle-based immunomodulatory approach that may have applications in radiotherapy and beyond.</p>","PeriodicalId":29,"journal":{"name":"Bioconjugate Chemistry","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioconjugate Chemistry","FirstCategoryId":"1","ListUrlMain":"https://doi.org/10.1021/acs.bioconjchem.4c00488","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
ATP (adenosine triphosphate) and HMGB1 (high mobility group box 1 protein) are key players in treatments that induce immunogenic cell death (ICD). However, conventional therapies, including radiotherapy, are often insufficient to induce ICD. In this study, we explore a strategy using nanoparticle-loaded macrophages as a source of ATP and HMGB1 to complement radiation-induced intrinsic and adaptive immune responses. To this end, we tested three inorganic particles, namely, iron oxide nanoparticles (ION), aluminum oxide nanoparticles (AON), and zinc oxide nanoparticles (ZON), in vitro with bone marrow-derived dendritic cells (BMDCs) and then in vivo in syngeneic tumor models. Our results showed that ION was the most effective of the three nanoparticles in promoting the secretion of ATP and HMGB1 from macrophages without negatively affecting macrophage survival. Secretions from ION-loaded macrophages can activate BMDCs. Intratumoral injection of ION-loaded macrophages significantly enhanced tumor infiltration and activation of dendritic cells and cytotoxic T cells. Moreover, exogenous ION macrophages can enhance the efficacy of radiotherapy. In addition, direct injection of ION can also enhance the efficacy of radiotherapy, which is attributed to ION uptake by and stimulation of endogenous macrophages. Instead of directly targeting cancer cells, our strategy targets macrophages and uses them as a secretory source of ATP and HMGB1 to enhance radiation-induced ICD. Our research introduces a new nanoparticle-based immunomodulatory approach that may have applications in radiotherapy and beyond.
ATP(三磷酸腺苷)和HMGB1(高迁移率基团框1蛋白)是诱导免疫性细胞死亡(ICD)治疗的关键因素。然而,包括放疗在内的传统疗法往往不足以诱导免疫细胞死亡。在本研究中,我们探索了一种利用纳米颗粒负载的巨噬细胞作为 ATP 和 HMGB1 的来源来补充辐射诱导的内在和适应性免疫反应的策略。为此,我们用骨髓树突状细胞(BMDCs)在体外测试了三种无机颗粒,即氧化铁纳米颗粒(ION)、氧化铝纳米颗粒(AON)和氧化锌纳米颗粒(ZON),然后在体内的合成肿瘤模型中进行了测试。我们的研究结果表明,ION是三种纳米粒子中促进巨噬细胞分泌ATP和HMGB1最有效的一种,而不会对巨噬细胞的存活产生负面影响。ION负载的巨噬细胞分泌物可激活BMDCs。瘤内注射 ION 载体巨噬细胞可显著增强肿瘤浸润以及树突状细胞和细胞毒性 T 细胞的活化。此外,外源性 ION 巨噬细胞还能提高放疗的疗效。此外,直接注射 ION 也能提高放疗的疗效,这是因为 ION 被内源性巨噬细胞吸收并刺激了它们。我们的策略不是直接靶向癌细胞,而是靶向巨噬细胞,利用它们作为 ATP 和 HMGB1 的分泌源,增强放射诱导的 ICD。我们的研究引入了一种新的基于纳米粒子的免疫调节方法,这种方法可能会应用于放疗及其他领域。
期刊介绍:
Bioconjugate Chemistry invites original contributions on all research at the interface between man-made and biological materials. The mission of the journal is to communicate to advances in fields including therapeutic delivery, imaging, bionanotechnology, and synthetic biology. Bioconjugate Chemistry is intended to provide a forum for presentation of research relevant to all aspects of bioconjugates, including the preparation, properties and applications of biomolecular conjugates.